Angiotensin-converting enzyme inhibitors (ACEIs) have traditionally been considered the primary treatment for reducing mortality after acute myocardial infarction (MI), preventing the development of heart failure, and potentially preventing subsequent MIs [5]. This evidence concerns the gene ACE and heart failure.